文献速递肝病

孟德尔随机化分析显示非酒精性脂肪性肝病与重症COVID-19无因果关系

Mendelian Randomization Analysis Reveals No Causal Relationship Between Nonalcoholic Fatty Liver Disease and Severe COVID-19.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-02-03

该研究采用两样本孟德尔随机化分析,探讨非酒精性脂肪性肝病(NAFLD)及其相关指标与重症COVID-19的因果关系。英国生物银行数据单变量分析显示NAFLD与重症COVID-19显著相关(OR 3.06),但调整人口学和合并症因素后关联消失(OR 1.57,P=0.09)。孟德尔随机化分析表明NAFLD(OR 0.97)、丙氨酸氨基转移酶水平(OR 1.03)、脂肪变性分级(OR 1.08)、NAFLD活动度评分(OR 1.02)及纤维化分期(OR 1.01)均与重症COVID-19无关,而体重指数、腰围和臀围显示因果影响。结论认为NAFLD并非重症COVID-19的因果风险因素,既往观察性关联可能归因于肥胖。

要点

  • 孟德尔随机化分析未发现NAFLD与重症COVID-19存在因果关系。
  • 体重指数(OR 1.73)、腰围(OR 1.76)和臀围(OR 1.33)显示对重症COVID-19有因果影响。
  • 观察性关联在调整合并症后消失,提示肥胖可能是混杂因素。

核心结论

  • 没有证据支持NAFLD是重症COVID-19的因果风险因素。
  • 既往观察性关联可能归因于NAFLD与肥胖之间的相关性。

研究设计与样本

  • 两样本孟德尔随机化分析,利用大规模队列数据。
  • 进行全基因组荟萃分析以识别与NAFLD相关的单核苷酸多态性。
  • 还检查了NAFLD的20个主要合并症因素对重症COVID-19的影响。

主要发现

  • 英国生物银行数据单变量分析显示NAFLD与重症COVID-19显著相关(OR 3.06;P=1.07×10⁻⁶)。
  • 调整人口学和合并症因素后,该关联消失(OR 1.57;P=0.09)。
  • 孟德尔随机化分析显示NAFLD(OR 0.97;P=0.61)、丙氨酸氨基转移酶水平(OR 1.03;P=0.47)、脂肪变性分级(OR 1.08;P=0.41)、NAFLD活动度评分(OR 1.02;P=0.39)和纤维化分期(OR 1.01;P=0.87)与重症COVID-19无关。
  • 在所有NAFLD相关合并症因素中,仅体重指数(OR 1.73;P=7.65×10⁻⁹)、腰围(OR 1.76;P=2.58×10⁻⁵)和臀围(OR 1.33;P=7.26×10⁻³)显示对重症COVID-19有因果影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The coronavirus disease 2019 (COVID-19) pandemic has witnessed more than 4.5 million deaths as of the time of writing. Whether nonalcoholic fatty liver disease (NAFLD) increases the risk for severe COVID-19 remains unclear. We sought to address this question using 2-sample Mendelian randomization (TSMR) analysis approaches in large cohorts. METHODS: We performed large-scale TSMR analyses to examine whether there is a causal relationship between NAFLD, serum alanine aminotransferase, grade of steatosis, NAFLD Activity Score, or fibrosis stage and severe COVID-19. To maximize the power of this analysis, we performed a genome-wide meta-analysis to identify single nucleotide polymorphisms associated with NAFLD. We also examined the impact of 20 major comorbid factors of NAFLD on severe COVID-19. RESULTS: Univariate analysis of the UK Biobank data demonstrated a significant association between NAFLD and severe COVID-19 (odds ratio [OR], 3.06; P = 1.07 × 10-6). However, this association disappeared after demographic and comorbid factors were adjusted (OR, 1.57; P = .09). TSMR study indicated that NAFLD (OR, 0.97; P = .61), alanine aminotransferase level (OR, 1.03; P = .47), grade of steatosis (OR, 1.08; P = .41), NAFLD Activity Score (OR, 1.02; P = .39), and fibrosis stage (OR, 1.01; P = .87) were not associated with severe COVID-19. Among all NAFLD-related comorbid factors, body mass index (OR, 1.73; P = 7.65 × 10-9), waist circumference (OR, 1.76; P = 2.58 × 10-5), and hip circumference (OR, 1.33; P = 7.26 × 10-3) were the only ones demonstrated a causal impact on severe COVID-19. CONCLUSIONS: There is no evidence supporting that NAFLD is a causal risk factor for severe COVID-19. Previous observational associations between NAFLD and COVID-19 are likely attributed to the correlation between NAFLD and obesity.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Li J, Tian A, Zhu H, et al. Mendelian Randomization Analysis Reveals No Causal Relationship Between Nonalcoholic Fatty Liver Disease and Severe COVID-19. Clin Gastroenterol Hepatol. 2022. PMID: 35124268. doi:10.1016/j.cgh.2022.01.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。